These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34856868)

  • 21. An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines.
    Bayani F; Hashkavaei NS; Arjmand S; Rezaei S; Uskoković V; Alijanianzadeh M; Uversky VN; Ranaei Siadat SO; Mozaffari-Jovin S; Sefidbakht Y
    Prog Biophys Mol Biol; 2023 Mar; 178():32-49. PubMed ID: 36801471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon.
    Powell J; Piszczatoski CR
    Ann Pharmacother; 2022 Sep; 56(9):1058-1064. PubMed ID: 35012364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of SARS-CoV-2-Specific Antibodies in Human Breast Milk and Their Neutralizing Capacity after COVID-19 Vaccination: A Systematic Review.
    Nicolaidou V; Georgiou R; Christofidou M; Felekkis K; Pieri M; Papaneophytou C
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
    Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
    BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
    Sharma O; Sultan AA; Ding H; Triggle CR
    Front Immunol; 2020; 11():585354. PubMed ID: 33163000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty
    Ando M; Satonaga Y; Takaki R; Yabe M; Kan T; Omote E; Yamasaki T; Komiya K; Hiramatsu K
    Int J Infect Dis; 2022 Nov; 124():187-189. PubMed ID: 36122668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mRNA Vaccines against SARS-CoV-2: Advantages and Caveats.
    Echaide M; Chocarro de Erauso L; Bocanegra A; Blanco E; Kochan G; Escors D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
    Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN
    Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A global survey in the developmental landscape of possible vaccination strategies for COVID-19.
    Gasmi A; Srinath S; Dadar M; Pivina L; Menzel A; Benahmed AG; Chirumbolo S; Bjørklund G
    Clin Immunol; 2022 Apr; 237():108958. PubMed ID: 35218966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants.
    Damasceno DHP; Amaral AA; Silva CA; Simões E Silva AC
    Curr Med Chem; 2022; 29(15):2673-2690. PubMed ID: 34473613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
    Al-Kassmy J; Pedersen J; Kobinger G
    Viruses; 2020 Aug; 12(8):. PubMed ID: 32784685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
    Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
    Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants.
    Li T; Luo KQ
    Int J Biol Sci; 2022; 18(12):4642-4647. PubMed ID: 35874950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers].
    Çiçek K; Özkaya Y; Eser E; Buran ZC; Öztürk Arıkan ZÖ; Akçalı S; Erbay Dündar P; Cengiz Özyurt B; Şenol Akar Ş; Özer D; Karadağ Yalçın F
    Mikrobiyol Bul; 2023 Apr; 57(2):238-251. PubMed ID: 37067208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 vaccines: a triumph of science and collaboration.
    Golob JL; Lugogo N; Lauring AS; Lok AS
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33822773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.